Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
HCWB Stock Forecast 2025-2026
$1.98
Current Price
$5.35M
Market Cap
Buy 1
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to HCWB Price Targets
+1,667.7%
To High Target of $35.00
+1,667.7%
To Median Target of $35.00
+1,667.7%
To Low Target of $35.00
HCWB Price Momentum
-6.6%
1 Week Change
-34.4%
1 Month Change
-87.7%
1 Year Change
-88.9%
Year-to-Date Change
-95.2%
From 52W High of $41.20
+7.6%
From 52W Low of $1.84
📊 TOP ANALYST CALLS
Did HCWB Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if HCW Biologics is one of their latest high-conviction picks.
Latest HCWB Stock Price Targets & Analyst Predictions
Based on our analysis of 5 Wall Street analysts, HCWB has a bullish consensus with a median price target of $35.00 (ranging from $35.00 to $35.00). The overall analyst rating is N/A (N/A/10). Currently trading at $1.98, the median forecast implies a 1,667.7% upside. This outlook is supported by 1 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Michael Okunewitch at Maxim Group, projecting a 1,667.7% upside. Conversely, the most conservative target is provided by Michael Okunewitch at Maxim Group, suggesting a 1,667.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
HCWB Analyst Ratings
1
Buy
0
Hold
0
Sell
HCWB Price Target Range
Low
$35.00
Average
$35.00
High
$35.00
Current: $1.98
Latest HCWB Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for HCWB.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 29, 2025 | Maxim Group | Michael Okunewitch | Buy | Maintains | $35.00 |
| Jun 1, 2023 | EF Hutton | Tony Butler | Buy | Assumes | $9.00 |
| Apr 19, 2023 | EF Hutton | Constantine Davides | Buy | Reiterates | $9.00 |
| Mar 30, 2023 | EF Hutton | Constantine Davides | Buy | Reiterates | $9.00 |
| Mar 23, 2023 | EF Hutton | Constantine Davides | Buy | Reiterates | $9.00 |
| Nov 8, 2022 | JonesTrading | Soumit Roy | Buy | Initiates | $8.00 |
| Mar 24, 2022 | Maxim Group | Michael Okunewitch | Buy | Initiates | $4.00 |
| Nov 19, 2021 | EF Hutton | Buy | Initiates | $N/A |
HCW Biologics Inc. (HCWB) Competitors
The following stocks are similar to HCW Biologics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
HCW Biologics Inc. (HCWB) Financial Data
HCW Biologics Inc. has a market capitalization of $5.35M with a P/E ratio of -0.1x. The company generates $422,026 in trailing twelve-month revenue with a 37.4% profit margin.
Revenue growth is -96.3% quarter-over-quarter, while maintaining an operating margin of -21,095.3% and return on equity of +443.5%.
Valuation Metrics
Market Cap
$5.35M
Enterprise Value
$11.22M
P/E Ratio
-0.1x
PEG Ratio
0.0x
Price/Sales
13.3x
Growth & Margins
Revenue Growth (YoY)
-96.3%
Gross Margin
+20.0%
Operating Margin
-21,095.3%
Net Margin
+37.4%
EPS Growth
-96.3%
Financial Health
Cash/Price Ratio
+20.5%
Current Ratio
0.1x
Debt/Equity
-3.2x
ROE
+443.5%
ROA
-31.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
HCW Biologics Inc. (HCWB) Business Model
About HCW Biologics Inc.
What They Do
Develops immunotherapies for age-related diseases and cancer.
Business Model
HCW Biologics Inc. generates revenue by developing proprietary biologics aimed at treating senescence-associated diseases, particularly in oncology and regenerative medicine. Their focus on innovative therapeutic solutions allows them to address significant unmet healthcare needs, which can lead to market opportunities as they advance through research and development stages.
Additional Information
The company is positioned at the intersection of biotechnology and therapeutic innovation, which may enhance its appeal to investors looking for impactful contributions in the pharmaceutical landscape, particularly for aging populations.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
36
CEO
Dr. Hing C. Wong Ph.D.
Country
United States
IPO Year
2021
Website
www.hcwbiologics.comHCW Biologics Inc. (HCWB) Latest News & Analysis
Latest News
Quick Summary
HCW Biologics Inc. has dosed the first patient in a multi-center trial for HCW9302, targeted at treating alopecia areata, marking a step in developing novel immunotherapies.
Why It Matters
The dosing of the first patient in HCW9302's trial signals progress in developing a novel treatment for autoimmune diseases, potentially boosting HCWB's stock value and market position.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
HCW Biologics Inc. (NASDAQ: HCWB) reported its third-quarter financial results for 2025, focusing on developing immunotherapies to address inflammation-related diseases.
Why It Matters
HCW Biologics' financial results and business highlights indicate its progress in immunotherapy development, which could impact stock performance and investor confidence in the biopharmaceutical sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
A new Tetra-valent T-cell engager aims to improve upon bi-specific T-cell engagers (BiTE) by enhancing manufacturability, safety, and treating various solid tumors.
Why It Matters
Advancements in T-cell engagers could enhance treatment efficacy and safety in oncology, potentially leading to increased market share and revenue for companies involved in developing these therapies.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
HCW Biologics Inc. (NASDAQ: HCWB) will participate in the 2025 Maxim Growth Summit on October 22-23 in NYC, focusing on immunotherapies targeting chronic inflammation.
Why It Matters
HCW Biologics' participation in the Maxim Growth Summit highlights its commitment to innovation and may attract investor interest, potentially influencing stock performance and market perception.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
The news excerpt does not provide any specific information or context relevant to investors. It only mentions a video titled "What This Means."
Why It Matters
The absence of specific details in the news excerpt leaves ambiguity, potentially affecting investor sentiment and decision-making based on the anticipated content of the video.
Source: GlobeNewsWire
Market Sentiment:
Neutral
HCW Biologics, a Shareholder of Wugen, Congratulates Wugen on Its Recent Successful Equity Financing
2 months ago
Quick Summary
Wugen closed a $115 million equity financing led by Fidelity Management, with participation from several prominent investors, enhancing its financial position in immunotherapy development.
Why It Matters
Wugen's $115 million equity financing boosts its capital for immunotherapy development, signaling strong investor confidence and potential growth, impacting stock performance and market sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About HCWB Stock
What is HCW Biologics Inc.'s (HCWB) stock forecast for 2026?
Based on our analysis of 5 Wall Street analysts, HCW Biologics Inc. (HCWB) has a median price target of $35.00. The highest price target is $35.00 and the lowest is $35.00.
Is HCWB stock a good investment in 2026?
According to current analyst ratings, HCWB has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.98. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for HCWB stock?
Wall Street analysts predict HCWB stock could reach $35.00 in the next 12 months. This represents a 1,667.7% increase from the current price of $1.98. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is HCW Biologics Inc.'s business model?
HCW Biologics Inc. generates revenue by developing proprietary biologics aimed at treating senescence-associated diseases, particularly in oncology and regenerative medicine. Their focus on innovative therapeutic solutions allows them to address significant unmet healthcare needs, which can lead to market opportunities as they advance through research and development stages.
What is the highest forecasted price for HCWB HCW Biologics Inc.?
The highest price target for HCWB is $35.00 from Michael Okunewitch at Maxim Group, which represents a 1,667.7% increase from the current price of $1.98.
What is the lowest forecasted price for HCWB HCW Biologics Inc.?
The lowest price target for HCWB is $35.00 from Michael Okunewitch at Maxim Group, which represents a 1,667.7% increase from the current price of $1.98.
What is the overall HCWB consensus from analysts for HCW Biologics Inc.?
The overall analyst consensus for HCWB is bullish. Out of 5 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $35.00.
How accurate are HCWB stock price projections?
Stock price projections, including those for HCW Biologics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 7, 2025 8:31 AM UTC